Christopher Ryan Sullivan, Chief Financial Officer, on August 17, 2026, sold 72,725 shares in Avalo Therapeutics (AVTX) for $1,450,419. Following the Form 4 filing with the SEC, Sullivan has control over a total of 39,900 common shares of the company, with 39,900 shares held directly.
SEC Filing: